ImmunoACT Achieves Profitability with India's First CAR-T Therapy, Treating Over 350 Cancer Patients
核心洞察
ImmunoACT (搜索) reported ₹62 crore in revenue and ₹12 crore profit before tax in FY25, marking rare profitability for an Indian biotech startup in its first full year of operations.
The company's NexCAR19 therapy, priced 90% lower than US and European counterparts, has been administered to over 350 patients across 70 hospitals since its April 2024 launch.
NexCAR19 demonstrated significant clinical benefits with 40% progression-free survival in B-cell non-Hodgkin lymphoma (搜索) and 60% in B-cell acute lymphoblastic leukemia (搜索) patients.
Mumbai-based ImmunoACT (搜索) has achieved a rare milestone in India's biotech landscape, reporting profitability in its first full year of operations while delivering the country's first homegrown CAR-T cell therapy to cancer patients. The company generated ₹62 crore in revenue and ₹12 crore in profit before tax in FY25, representing a dramatic increase from ₹11 crore in revenue the previous year.
Commercial Success of NexCAR19
ImmunoACT (搜索)'s flagship therapy, NexCAR19, received approval from India's central drug regulatory agency in October 2023 and launched commercially in April 2024. The therapy has been administered to over 350 patients across 70 hospitals throughout India, demonstrating significant market penetration in its first year of availability.
NexCAR19 entered the market at approximately 90% lower cost compared to similar therapies available in the US and Europe, including products from Novartis and Gilead. Initially priced at ₹42 lakh per dose, the cost has decreased to around ₹30 lakh, with further price reductions anticipated as production scales and demand increases. Each treatment is delivered as a single infusion, offering a "one-and-done" therapeutic approach.
Clinical Efficacy and Treatment Approach
The therapy has demonstrated substantial clinical benefits in treating specific cancer types where conventional options like immunotherapy or bone marrow transplants have failed. NexCAR19 showed progression-free survival benefits of 40% in B-cell non-Hodgkin lymphoma (搜索) (NHL) and 60% in B-cell acute lymphoblastic leukemia (搜索) (B-ALL), representing significant improvements over standard of care treatments.
CAR-T therapy works by extracting a patient's immune cells and re-engineering them through complex processes before infusing them back into the patient. These modified cells are designed to recognize and kill cancer cells, potentially providing longer remission periods compared to conventional treatment options.
Company Background and Leadership
ImmunoACT (搜索) was founded by immunologist Dr. Rahul Purwar in 2013 following his research experience in the US and Germany. The company was spun off from the department of bioengineering at IIT Bombay in 2018. Hyderabad-based drug maker Laurus Labs holds approximately 34% equity stake in the company.
The company recently appointed V. Simpson Immanuel, former managing director of Roche India (搜索), as strategic advisor. Immanuel brings leadership experience from global organizations including Merck and Eli Lilly. According to Dr. Purwar, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion. Simpson brings that rare combination."
Market Context and Competition
India's CAR-T sector is experiencing parallel developments from multiple companies. Earlier this year, Immuneel Therapeutics (搜索), backed by Kiran Mazumdar-Shaw and oncologist Siddhartha Mukherjee, secured approval for Qartemi (搜索), its cell therapy for adult B-cell non-Hodgkin lymphoma (搜索). Major pharmaceutical companies including Cipla, Dr. Reddy's Labs (搜索), and Bharat Biotech are investing heavily in CAR-T development.
The global CAR-T therapy market is positioned for substantial growth, with analysts estimating expansion from approximately $10 billion currently to $134 billion by 2034. This growth trajectory reflects the significant investment flowing into research and commercialization of these advanced cancer treatments.
Manufacturing and Accessibility Challenges
Cell and gene therapies face inherent challenges related to toxicity and access, as manufacturing processes are complex and require several weeks to prepare treatments. However, scientists note that these therapies typically demonstrate better patient outcomes compared to multi-specific antibodies, which require continuous dosing and face the drawback of immune escape where cancer cells can detect and evade treatment.
ImmunoACT (搜索)'s achievement in developing an affordable CAR-T therapy while maintaining profitability positions India as an emerging player in global cell and gene therapy innovation, potentially expanding access to advanced cancer treatments in low- and middle-income countries.